Squarepoint’s Adverum Biotechnologies ADVM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-11,271
| Closed | -$51.1K | – | 4199 |
|
|
2025
Q3 | $51.1K | Sell |
11,271
-10,381
| -48% | -$30.6K | ﹤0.01% | 4225 |
|
|
2025
Q2 | $46.6K | Buy |
+21,652
| New | +$60.6K | ﹤0.01% | 4314 |
|
|
2024
Q4 | – | Sell |
-49,844
| Closed | -$350K | – | 4973 |
|
|
2024
Q3 | $350K | Sell |
49,844
-59,134
| -54% | -$429K | ﹤0.01% | 3349 |
|
|
2024
Q2 | $748K | Buy |
108,978
+81,808
| +301% | +$761K | ﹤0.01% | 2776 |
|
|
2024
Q1 | $384K | Buy |
27,170
+22,937
| +542% | +$349K | ﹤0.01% | 3226 |
|
|
2023
Q4 | $31.9K | Buy |
+4,233
| New | +$38.6K | ﹤0.01% | 3887 |
|
|
2022
Q1 | – | Sell |
-1,506
| Closed | -$27K | – | 2752 |
|
|
2021
Q4 | $27K | Sell |
1,506
-1,877
| -55% | -$37.6K | ﹤0.01% | 3075 |
|
|
2021
Q3 | $73K | Buy |
3,383
+702
| +26% | +$17.9K | ﹤0.01% | 2726 |
|
|
2021
Q2 | $94K | Buy |
+2,681
| New | +$144K | ﹤0.01% | 3026 |
|
|
2021
Q1 | – | Sell |
-2,582
| Closed | -$280K | – | 3045 |
|
|
2020
Q4 | $280K | Sell |
2,582
-6,622
| -72% | -$819K | ﹤0.01% | 2256 |
|
|
2020
Q3 | $948K | Buy |
+9,204
| New | +$1.38M | 0.01% | 1029 |
|
|
2020
Q1 | – | Sell |
-11,197
| Closed | -$1.29M | – | 1806 |
|
|
2019
Q4 | $1.29M | Sell |
11,197
-8,870
| -44% | -$782K | 0.01% | 1182 |
|
|
2019
Q3 | $1.09M | Buy |
20,067
+18,667
| +1,333% | +$2.1M | 0.01% | 1172 |
|
|
2019
Q2 | $166K | Buy |
+1,400
| New | +$116K | ﹤0.01% | 2142 |
|
|
2018
Q2 | – | Sell |
-2,964
| Closed | -$172K | – | 1718 |
|
|
2018
Q1 | $172K | Buy |
+2,964
| New | +$185K | ﹤0.01% | 1520 |
|
|
2017
Q4 | – | Sell |
-3,180
| Closed | -$116K | – | 2051 |
|
|
2017
Q3 | $116K | Buy |
3,180
+2,150
| +209% | +$59.7K | ﹤0.01% | 1495 |
|
|
2017
Q2 | $26K | Sell |
1,030
-24
| -2% | -$656 | ﹤0.01% | 1484 |
|
|
2017
Q1 | $28K | Buy |
+1,054
| New | +$30K | ﹤0.01% | 1467 |
|
Squarepoint's ADVM Position: Q4 2025 in Review
Squarepoint sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 11,271 shares — an estimated $51.1K sold.
Squarepoint first reported a position in ADVM in Q1 2017 and held it in 18 quarters. The position peaked at $1.29M in Q4 2019. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.
- Squarepoint reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
- Squarepoint sold 11,271 Adverum Biotechnologies shares in Q4 2025, an estimated $51.1K.
- Squarepoint first reported a position in Adverum Biotechnologies in Q1 2017 and held it in 18 quarters.
- Squarepoint's Adverum Biotechnologies position peaked at $1.29M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.
Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.